Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors
Contact:
NCT Number:
Protocol:
AAAU9937
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this study is to learn how well RP-1664 alone works to treat advanced solid tumor. RP-1664 has not been approved by the Food and Drug Administration (FDA). RP- 1664 has not been given to humans prior to this study.
Are you Eligible? (Inclusion Criteria)
- Must be 18 years old or older - Able to swallow and retail oral medications - Ability to consume a high-fat meal and fast for 12 hours
Specialty Area(s)
Bladder Cancer , Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Skin cancers, Melanoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Testicular Cancer, Thyroid Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
